Group Health Cooperative of Puget Sound

全球 卫生理事会（ GHC ）最新 报告强调卫生在抗击抗微生物药物耐药性和未来疫情方面的关键作用 伦敦 2023年5月6日 /美通社/ -- 作为由卫生和感染预防领域知名专家组成的独立委员会，全球卫生理事会 (GHC) 今天发布了一份新报告，呼吁采取紧急行动，在新冠疫情之后的疫情防范计划中优先关注家庭和社区环境中的卫生问题。全球卫生理事会敦促各国政府和政策制定者提高对卫生的重视程度，以保护千百万人的生命。 随着新冠疫情显示出结束迹象，抗微生物药物耐药性 (AMR) 的"无声流行病"仍在持续，而AMR被认为是人类健康面临的最大威胁之一。2019年，495万例死亡与AMR有关，突显出它作为人类健康最大威胁之一的影响。如不采取行动，到2050年这一数字可能会上升到每年1000万例死亡。全球卫生理事会这份标题为《让卫生成为重要事项》（Making Hygiene Matter）的报告强调了家庭和社区卫生在降低感染发生率和ARM流行率方面的重要性。 该报告确定了变革的四大支柱，包括在日常环境中保持卫生意识、通过卫生规范减少对抗生素的需求、认识到有效卫生的经济益处，以及推动行为改变以建立强大的卫生习惯。 微生物学家、美国波士顿西蒙斯大学名誉教授兼全球卫生理事会主席Elizabeth Scott表示： "全球卫生理事会的新报告非常及时，提供了切实可行的卫生变革建议。我们需要立即采取行动来保护公众健康，而良好的卫生对于预防感染和拯救生命而言，是最具成本效益、最简单易行也最易获得的解决方案之一。" 在新冠疫情期间加强卫生规范的有益次级效应现已显现。自疫情开始以来，其他一些疾病的患病率已呈现出下降，包括季节性流感和其他季节性呼吸道病毒病例，而儿童常见疾病的患病人数显著下降。科学家们确认，现在已出现了一个"明确共识"，那就是其他呼吸道疾病患病率在疫情期间下降的原因在于人类行为和基于卫生的缓解措施。 全球卫生理事会敦促各国政府、政策制定者和卫生当局在应对包括AMR在内的现有和未来传染病威胁时采纳并实施报告中的建议。

Former McKesson Executive to Enhance Organizational Analytics and Data Strategy ATLANTA, Dec. 7, 2022 /PRNewswire/ -- OncoHealth®, a leading digital health company dedicated to oncology, today announced the appointment of Susan Hoang, PharmD, as the company's Chief Data & Analytics Officer. An innovative and results-oriented healthcare data and analytics leader with experience developing and launching revolutionary value-based care programs, Hoang will be responsible for building out and maintaining OncoHealth's ongoing organizational analytics and data strategy. She will be focused on the use of advanced analytics methodologies for supporting external customers, internal processes, and research and development initiatives. Continue Reading OncoHealth, a leading digital health company dedicated to oncology, taps Susan Hoang, PharmD, as the company’s Chief Data & Analytics Officer. "Joining OncoHealth aligns with my personal mission to enhance patient access to high-value healthcare, and I'm thrilled to align with a company that has a proven track record of leveraging real-world data and analytics to support high-quality, high-value oncology care," said Hoang. "I look forward to working with OncoHealth's talented team to expand on the solid data analytics foundation already established, so we can further enable data-driven decisions to solve the complexities of cancer." A clinical pharmacist by training, Hoang comes from McKesson where she held positions as Vice President of Oncology Data & Analytics and Vice President of Strategic Oncology Pharmacy. She previously held global strategic marketing and oncology category marketing roles at GE Healthcare, led clinical content development at US Oncology and oversaw the clinical pharmacy team at Group Health Cooperative (now Kaiser Washington). Hoang was also part of the clinical faculty at the University of Washington. She is the author of the Ground Truth blog. "We are pleased to add Susan's expertise to our leadership team," said Rick Dean, Chief Executive Officer, OncoHealth. "Her impressive background, growth mindset, customer focus, team enablement and design thinking will be critical in our efforts to develop new solutions and insights for our health plan clients and members with cancer." About OncoHealth OncoHealth is a leading digital health company dedicated to helping health plans, employers, providers, patients, and life science researchers navigate the physical, mental, and financial complexities of cancer through technology-enabled services and real-world data analytics. Supporting more than 7 million people in the US and Puerto Rico, OncoHealth offers digital solutions for treatment review, real-world evidence, and telehealth across all cancer types. For more information, visit . SOURCE OncoHealth

GAROFALO HEALTH CARE S.P.A. COMPLETES THE ACQUISITION OF "GRUPPO VENETO DIAGNOSTICA E RIABILITAZIONE" (GVDR), ONE OF THE LEADING ACCREDITED PRIVATE DIAGNOSTIC CENTRES IN THE VENETO REGION DEFINED THE NEW GOVERNANCE OF THE ACQUIRED COMPANY IN THE FURROW OF BUSINESS CONTINUITY, AS PER THE GHC GROUP'S CONSOLIDATED PRACTICE Rome, December 6, 2022 - Garofalo Health Care S.p.A. ("GHC"), listed on the Euronext STAR Milan market of the Italian Stock Exchange, informs that today the closing was completed for the acquisition of 100% of Gruppo Veneto Diagnostica e Riabilitazione S.r.l. ("GVDR"), founded in 1988 by the spouses Giuseppe Caraccio and Maria Stella Zaia. The acquisition was made through a vehicle company called GHC Project 9 S.r.l., wholly owned by GHC. On the occasion of the closing, following the consolidated practice of the GHC Group, the governance of the Target was renewed with the appointment of the following Directors: Mr. Giuseppe Caraccio, Chairman, Mrs. Maria Stella Zaia, Chief Executive Officer, Mrs. Maria Laura Garofalo, Mrs. Alessandra Rinaldi Garofalo, Mrs. Claudia Garofalo - Directors. This composition of the Board of Directors confirms compliance with the distinctive elements of the Group's post M&A discipline, through: (i) the maintenance of the management continuity of the facility, guaranteed by the role of Chairman attributed to Mr. Caraccio (who will maintain also the position of Medical Director) and the role of Chief Executive Officer attributed to Mrs. Zaia, both founding members of the facility, (ii) the commitment to a fast and full integration between the newly acquired reality and the facilities of the GHC Group, directly guaranteed by the presence of Mrs. Maria Laura Garofalo, who will ensure the support of the Holding and all of GHC in support of future planning. Mrs. Maria Laura Garofalo, Chief Executive Officer of the GHC Group, stated: "The positive conclusion of this operation, the ninth since the IPO, confirms GHC's ability to acquire structures of excellence and with incremental performance compared to those of the Group. In particular, the acquisition of GVDR ensures GHC an increasingly widespread presence in the Veneto Region, also covering the provinces of Padua, Treviso and Venice, as well as enabling important synergies to be established with the other Group facilities present in the same Region. I would also like to highlight how the growth prospects assumed for the next financial year are already finding confirmation in 2022, thanks to budget increases for the reduction of waiting lists - already contractually agreed - totalling approx. €600k and to the further growth of the private business". Mr. Giuseppe Caraccio, Chairman of the Board of Directors and Mrs. Mariastella Zaia, CEO, stated: "We are happy to become part of a family of Italian entrepreneurs. Our role will be to help broaden the Group's objectives, generating - especially for the area in which we operate - further growth opportunities given by the quality of our services and the continuous development of our current activities, also in innovative fields." For the payment of the price, equal to €24.9M, GHC used both the available cash and a bank loan, having the availability of a Financing Line for new acquisitions for a total of €81M. The development guidelines identified after the Due Diligence activity and already communicated to the market are fully confirmed. In particular, these refer to: (i) the opening of a new building in front of the Cadoneghe facility in order to further expand private activities - with estimated impacts from FY2023, (ii) the increase of private activity at the current facilities - with estimated impacts already from FY2022, and (iii) the recognition of additional NHS budgets for the reduction of waiting lists - again with estimated impacts already from FY2022. In 2021 GVDR reported Revenues of approx. €12.0M, of which approx. 54% from accredited activities with the Veneto Region and approx. 46% from private activities, up approx. 10% on 2019 (year not affected by the Covid emergency). The Adjusted and pre-efficiencies normalized EBITDA was approx. €2.8M, with a margin of 23.6% - higher than the Group average (17.9% in 9M 2022).